



Prior Authorization Criteria

Ocrevus (*ocrelizumab*) PA CRITERIA:

Ocrevus is indicated for the treatment of

- Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults
- Primary progressive MS, in adults. **No other disease-modifying MS medications are indicated for use in primary progressive MS.**

Ocrevus should be prescribed by, or in consultation with, a physician who specializes in the treatment of MS and/or a neurologist.

Select the diagnosis below:

- | | |
|--|--------------------|
| <input type="checkbox"/> Primary progressive multiple sclerosis (PPMS) | ICD-10 code: _____ |
| <input type="checkbox"/> Relapsing forms of multiple sclerosis (MS) | ICD-10 code: _____ |
| <input type="checkbox"/> Other diagnosis: _____ | ICD 10 code: _____ |

FDA-APPROVED INDICATIONS

1. RELAPSING REMITTING FORMS OF MULTIPLE SCLEROSIS (RRMS) (Approval: 6 Months)

Approve for 6 months if the patient meets **ALL** of the following criteria (**A, B, C, and D**):

Yes No Age of patient is within the age range as recommended by the FDA label
AND

Yes Relapsing form of multiple sclerosis (MS) [relapsing forms of MS are relapsing-remitting MS {RRMS}, secondary-progressive MS {SPMS} with relapses, or progressive-relapsing MS {PRMS}];
AND

Yes Previous trial in the last six months of at least two preferred MS drugs which are contraindicated or not tolerated or ineffective; **AND**

Please indicate which of the following describe the evidence of treatment ineffectiveness:

- Yes, No Increasing clinical relapses (defined as 2 or more relapses in a year, or one severe relapse associated with either poor recover or MRI lesion progression),
- Yes, No CNS lesion progression by MRI (increased number or volume of gadolinium-enhancing lesions, T2 hyperintense lesions or T1 hypointense lesions),
- Yes, No Worsening disability (sustained worsening of Expanded Disability Status Scale (EDSS) score or neurological examination findings),
- Yes, No Continues to have worsening disability as evidenced by decreased mobility and/or ability to perform activities of daily living.
- Other (please explain): _____

Yes This is a particularly aggressive initial disease course, as defined by meeting at least one of the following:



MISSISSIPPI DIVISION OF
MEDICAID

- Yes, No EDSS score of ≥ 4 within 5 years of onset; OR
- Yes, No Multiple (two or more) relapses with incomplete resolution in the past year; OR
- Yes, No At least 2 MRI studies showing new or enlarging T2 lesions or gadolinium-enhancing lesions despite treatment over 6 months; OR
- Yes, No Presence of spinal or brainstem lesions on MRI.

2. PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS (PPMS) (Approval: 6 Months)

- Yes No Age of patient is within the age range as recommended by the FDA label
- AND**

Prescribing physician attests that patient is thought to have PPMS as evidenced by:

- Yes, No --Are there one or more brain T2 lesions in at least one area characteristic for MS (periventricular, juxacortical, cortical or infratentorial?)
- OR**
- Yes, No --Are there two or more T2 lesions in the spinal cord?
- OR**
- Yes, No --Is there positive CSF (isoelectric focusing evidence of oligoclonal IgG bands or increased IgG index, or both)?

Please indicate the length of disease progression (retrospectively or prospectively determined):

- < 1 year **OR** ≥ 1 year

CONDITIONS NOT RECOMMENDED FOR APPROVAL

Ocrevus has not been shown to be effective, or there are limited or preliminary data or potential safety concerns that are not supportive of general approval for the following conditions.

- Yes, No -**Current Use of Ocrevus with Other Disease-Modifying Agents Used for Multiple Sclerosis (MS)**
 - Ocrevus is not indicated for use in combination with other MS disease-modifying therapies and the safety and efficacy have not been adequately established.
- Yes, No -**Active Hepatitis B infection.**
 - OCREVUS is contraindicated in patients with active HBV confirmed by positive results for HBsAg and anti-HBV tests.
 - For patients who are negative for surface antigen (HBsAG) and positive for HB core antibody (HBcAb+) or are carriers of HBV (HbsAg+), consult liver disease experts before starting and during treatment.
 - Prior to initiating OCREVUS, perform Hepatitis–B Screening
Date: _____

REAUTHORIZATION REQUESTS: (Approval 12 months)

- Yes, No Continues to meet initial authorization criteria as applicable;
- AND**



- Yes, No Ocrevus was administered to patient in the past 6 months;
AND
- Yes, No Documentation of positive response to therapy (e.g., improved or maintained disease control evidenced by decreased or stabilized Expanded Disability Scale (EDSS) score or reductions in relapses or MRI lesions);
AND
- Yes, No Not using other MS disease-modifying therapies concurrently;
AND
- Yes, No There were no documented severe and / or potentially life threatening adverse event that occurred during or following the previous infusion;
AND
- Yes, No Does not have an active Hepatitis B infection

How Supplied: Intravenous Solution: 300mg /10 ml Vial

Ocrevus Dose: _____ Frequency: _____

Dosage and Administration:

- Initial Dose: 300 mg IV infusion on day 1, followed by a second 300 mg IV infusion 2 weeks later;
- Maintenance dose: 600 mg every 6 months (beginning 6 months after the first 300 mg dose)
- Pre-medicate with 100 mg of methylprednisolone (or an equivalent corticosteroid) administered IV approximately 30 minutes prior to each Ocrevus infusion to reduce the frequency and severity of infusion reactions. Pre-medicate with an antihistamine (e.g., diphenhydramine) approximately 30-60 minutes prior to each Ocrevus infusion to further reduce the frequency and severity of infusion reactions. The addition of an antipyretic (e.g., acetaminophen) may also be considered.
- Observe patient for at least 1 hour after infusion completion.

Ocrevus should be administered under the close supervision of an experienced healthcare professional with access to appropriate medical support to manage severe reactions such as serious infusion reactions.